Study S002204

Safety and Efficacy of Exenatide Taken Before Lunch and Before Dinner Compared With Before Breakfast and Before Dinner in Patients With Type 2 Diabetes Using Oral Antidiabetic Therapy

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT00359879
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: NONE
Status: COMPLETED
Enrollment: 377
Start: 2006-09
Primary completion: 2007-07
Lead sponsor: AstraZeneca
Conditions: Type 2 Diabetes
Interventions: DRUG:exenatide
Results posted: FALSE

Registered primary outcomes

Change in HbA1c (glycosylated hemoglobin) from Baseline to Week 12 [Baseline, Week 12]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0027566	Efficacy and safety of exenatide administered before the two largest daily meals of Latin American patients with type 2 diabetes. Forti A, Current medical research and opinion	2008	Randomized trial	PMID 18662495 DOI	cites ClinicalTrials.gov:NCT00359879; registry reference DERIVED:18662495